Observational studyClinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery2026
Simultaneous Head and Neck and Lung Cancers: Implications and Therapeutic Management Timing.
Observational study in Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Simultaneous Head and Neck and Lung Cancers: Implications and Therapeutic Management Timing.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to describe the characteristics of patients with simultaneous head and neck squamous cell carcinomas (HNSCCs) and lung cancer and to assess the impact of diagnosis-to-treatment interval (DTI) and treatment choices on outcomes. DESIGN AND
settingA bicentric retrospective observational study conducted between 2003 and 2020 in two tertiary referral academic hospitals.
participantsForty-three patients diagnosed with both HNSCC and lung cancer within 1 month were compared to a 1:2 control group of patients diagnosed with HNSCC alone. The groups were matched by tumour location, TNM stage and treatment centre. Multivariate analysis was used to assess factors influencing DTI, and survival analysis was conducted using the Kaplan-Meier estimator.
main outcome measuresPrimary outcomes included DTI and overall survival.
resultsPatients with simultaneous cancers were predominantly male (84%) with heavy smoking histories. Most HNSCC cases (84%) were diagnosed at advanced stages (III/IV), while lung cancers were predominantly early stage (I-II). Patients with simultaneous cancers had significantly longer DTIs (median 43 days, IQR [32.8-85.8]) compared to controls (28 days, IQR [19.0-38.0]) (p < 0.001; HR = 0.35, p = 0.0001). As expected, overall survival was markedly worse for patients with simultaneous cancers (median 17.8 months, 95% CI [12.6-31.0]) versus controls (56.5 months, 95% CI [38.4-], p < 0.001).
conclusionProlonged DTI may contribute to the poorer survival outcomes in patients with simultaneous cancers. Strategies to reduce delays, such as performing concurrent bronchoscopy and endoscopy, should be explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.